doi: 10.1007/s11606-007-0141-4. Epub 2007 Mar 7.
Bioidentical hormones for menopausal hormone therapy: variation on a theme
Affiliations
- PMID:17549577
- PMCID: PMC2219716
- DOI: 10.1007/s11606-007-0141-4
Item in Clipboard
Bioidentical hormones for menopausal hormone therapy: variation on a theme
Adriane Fugh-Berman et al. J Gen Intern Med.2007 Jul.
Display options
Format
Display options
Format
Abstract
Background: Progesterone creams and natural or bioidentical compounded estrogen preparations are being promoted to consumers as safe alternatives to conventional menopausal hormone therapy and as health-promoting tonics. No reliable data support these claims.
Safety: Natural hormones, including estradiol, estriol, estrone, and progesterone, can be expected to have the same adverse event profile as conventional menopausal hormone regimens.
Salivary hormone tests: Salivary tests may be used to persuade asymptomatic consumers to use hormones (or symptomatic patients to use higher doses than those needed to mitigate symptoms), a practice that can be expected to result in adverse events.
Similar articles
- Compounded or confused? Bioidentical hormones and menopausal health.Huntley AL.Huntley AL.Menopause Int. 2011 Mar;17(1):16-8. doi: 10.1258/mi.2011.011009.Menopause Int. 2011.PMID:21427420Review.
- Bioidentical hormone therapy: a review of the evidence.Cirigliano M.Cirigliano M.J Womens Health (Larchmt). 2007 Jun;16(5):600-31. doi: 10.1089/jwh.2006.0311.J Womens Health (Larchmt). 2007.PMID:17627398Review.
- The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?Holtorf K.Holtorf K.Postgrad Med. 2009 Jan;121(1):73-85. doi: 10.3810/pgm.2009.01.1949.Postgrad Med. 2009.PMID:19179815Review.
- Risks and effectiveness of compounded bioidentical hormone therapy: a case series.Davis R, Batur P, Thacker HL.Davis R, et al.J Womens Health (Larchmt). 2014 Aug;23(8):642-8. doi: 10.1089/jwh.2014.4770.J Womens Health (Larchmt). 2014.PMID:25111856Review.
- Bioidentical hormones for menopausal therapy.Sites CK.Sites CK.Womens Health (Lond). 2008 Mar;4(2):163-71. doi: 10.2217/17455057.4.2.163.Womens Health (Lond). 2008.PMID:19072518Review.
Cited by
- Defining bioidentical hormones for menopause-related symptoms.Whelan AM, Jurgens TM, Trinacty M.Whelan AM, et al.Pharm Pract (Granada). 2011 Jan;9(1):16-22. doi: 10.4321/s1886-36552011000100003. Epub 2011 Mar 15.Pharm Pract (Granada). 2011.PMID:25132885Free PMC article.
- Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making.Thompson JJ, Ritenbaugh C, Nichter M.Thompson JJ, et al.BMC Womens Health. 2017 Oct 2;17(1):97. doi: 10.1186/s12905-017-0449-0.BMC Womens Health. 2017.PMID:28969624Free PMC article.
- Bioidentical hormone therapy: Nova Scotia pharmacists' knowledge and beliefs.Whelan AM, Thebeau JP, Jurgens TM, Hurst E.Whelan AM, et al.Pharm Pract (Granada). 2012 Jul;10(3):159-67. doi: 10.4321/s1886-36552012000300006. Epub 2012 Sep 30.Pharm Pract (Granada). 2012.PMID:24155832Free PMC article.
- Bioidentical hormones, menopausal women, and the lure of the "natural" in U.S. anti-aging medicine.Fishman JR, Flatt MA, Settersten RA Jr.Fishman JR, et al.Soc Sci Med. 2015 May;132:79-87. doi: 10.1016/j.socscimed.2015.02.027. Epub 2015 Feb 19.Soc Sci Med. 2015.PMID:25795991Free PMC article.
- INDIVIDUALIZATION OF CUSTOM COMPOUNDED HORMONE THERAPY IN A PATIENT WITH CHEMOTHERAPY INDUCED PREMATURE OVARIAN INSUFFICIENCY AND IMPAIRED LIVER FUNCTION - CASE REPORT.Franić D, Sever M, Janež A, Franić-Ivanišević M, Jensterle M.Franić D, et al.Acta Clin Croat. 2019 Mar;58(1):167-172. doi: 10.20471/acc.2019.58.01.21.Acta Clin Croat. 2019.PMID:31363339Free PMC article.
References
- Hogg JA. Steroids, the steroid community, and Upjohn in perspective: a profile of innovation. Steroids. 1002;57:593–616. - PubMed
- {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '15595573', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15595573/'}]}
- Mahaguna V, McDermott JM, Zhang F, Ochoa F. Investigation of product quality between extemporaneously compounded progesterone vaginal suppositories and an approved progesterone vaginal gel. Drug Dev Ind Pharm. 2004;30(10):1069–78. - PubMed
- Food and Drug Administration. Available via the internet athttp://www.cfsan.fda.gov/~dms/cfsand04.html. Accessed 19 Sep 2006.
- None
- Women’s International Pharmacy. Especially Designed for Women. Youngtown, Ariz, and Madison, Wisc., USA: Women’s International Pharmacy; 8–9 April 2002.
- Premier Pharmacy. Available athttp://premier-pharmacy.com/abouthrt3.html. Accessed Jul 2005. (PDF no longer available)
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical